Grace Therapeutics, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $34.0M
- Price
- $2.20
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.29%
- Volume
- 159.8K
About
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Quick stats
Shares outstanding15.5M
Computed float8.3M
Float / shares53.7%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001444192
Websitehttps://www.gracetx.com
AI Summary
AI-generated1/32
standardneutralearnings
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update
Grace Therapeutics reported a Q1 net loss of $15.8 million, or $0.91 per share, compared to a loss of $3.4 million, or $0.21 per share, in the prior year period, driven primarily by a $13.5 million impairment charge for deprioritized assets GTx-101 and GTx-102.
The company announced a $10 million private placement financing, extending its cash runway through the end of calendar 2028 to fund manufacturing and regulatory work for its lead asset GTx-104.
Management confirmed that the FDA's Complete Response Letter identified no clinical safety or efficacy deficiencies, and the company is advancing a dual-source manufacturing strategy to address the remaining CMC and facility-level compliance items required for NDA resubmission.
Red flags
- Recorded full impairment of remaining IPR&D carrying value associated with GTx-101 and GTx-102 ($13.5M charge)
- NDA resubmission timing is contingent on external contract manufacturer remediation and technology transfer milestones